| Literature DB >> 27783676 |
Sulaf Alwassouf1,2, Vasiliki Christodoulou3, Laurence Bichaud1,2, Pantelis Ntais4, Apostolos Mazeris3, Maria Antoniou4, Remi N Charrel1,2.
Abstract
Phleboviruses transmitted by sandflies are endemic in the Mediterranean area. The last decade has witnessed the description of an accumulating number of novel viruses. Although, the risk of exposure of vertebrates is globally assessed, detailed geographic knowledge is poor even in Greece and Cyprus where sandfly fever has been recognized for a long time and repeatedly. A total of 1,250 dogs from mainland Greece and Greek archipelago on one hand and 422 dogs from Cyprus on the other hand have been sampled and tested for neutralising antibodies against Toscana virus (TOSV), Sandfly fever Sicilian virus (SFSV), Arbia virus, and Adana virus i.e. four viruses belonging to the 3 sandfly-borne serocomplexes known to circulate actively in the Mediterranean area. Our results showed that (i) SFSV is highly prevalent with 71.9% (50.7-84.9% depending on the region) in Greece and 60.2% (40.0-72.6%) in Cyprus; (ii) TOSV ranked second with 4.4% (0-15.4%) in Greece and 8.4% (0-11.4%) in Cyprus; (iii) Salehabad viruses (Arbia and Adana) displayed also substantial prevalence rates in both countries with values ranging from 0-22.6% depending on the region and on the virus strain used in the test. These results demonstrate that circulation of viruses transmitted by sand flies can be estimated qualitatively using dog sera. As reported in other regions of the Mediterranean, these results indicate that it is time to shift these viruses from the "neglected" status to the "priority" status in order to stimulate studies aiming at defining and quantifying their medical and veterinary importance and possible public health impact. Specifically, viruses belonging to the Sandfly fever Sicilian complex should be given careful consideration. This calls for implementation of direct and indirect diagnosis in National reference centers and in hospital microbiology laboratories and systematic testing of unelucidated febrile illness and central and peripheral nervous system febrile manifestations.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27783676 PMCID: PMC5081206 DOI: 10.1371/journal.pntd.0005063
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Characteristics of dogs tested in the study.
| Region | N° of sera | Prefecture | N° of sera | Male | Female | Ratio M/F | Median age |
|---|---|---|---|---|---|---|---|
| Attica | 410 | Attica | 410 | 79 | 331 | 0.24 | 24 |
| Central Macedonia | 129 | Chalkidiki | 62 | 36 | 26 | 1.38 | 60 |
| Imathia | 4 | 3 | 1 | 3.00 | 42 | ||
| Kilkis | 4 | 4 | 0 | - | 99 | ||
| Serres | 26 | 11 | 15 | 0.73 | 60 | ||
| Thessaloniki | 32 | 16 | 16 | 1.00 | 54 | ||
| Veria | 1 | 1 | 0 | - | 16 | ||
| Crete | 199 | Chania | 89 | 40 | 49 | 0.82 | 42 |
| Heraklion | 51 | 23 | 28 | 0.82 | 48 | ||
| Lassithi | 33 | 16 | 17 | 0.94 | 36 | ||
| Rethymno | 26 | 19 | 7 | 2.71 | 27 | ||
| East Macedonia and Thrace | 91 | Drama | 16 | 8 | 8 | 1.00 | 36 |
| Evros | 35 | 17 | 18 | 0.94 | 60 | ||
| Kavala | 21 | 15 | 6 | 2.50 | 30 | ||
| Rodopi | 19 | 9 | 10 | 0.90 | 24 | ||
| Epirus | 37 | Arta | 30 | 24 | 6 | 4.00 | 27 |
| Ioannina | 7 | 5 | 2 | 2.50 | 18 | ||
| Ioanian Islands | 79 | Corfu island | 79 | 49 | 30 | 1.63 | 48 |
| North Aegean | 81 | Chios island | 15 | 7 | 8 | 0.88 | 54 |
| Lesvos Island | 66 | 33 | 33 | 1.00 | 48 | ||
| Peloponesse | 60 | Argos | 3 | 1 | 2 | 0.50 | 96 |
| Arkadia | 56 | 26 | 30 | 0.87 | 48 | ||
| Korinthia | 1 | 1 | 0 | - | 36 | ||
| South Aegean | 30 | Cyclades | 19 | 12 | 7 | 1.71 | 60 |
| Dodecanese | 11 | 6 | 5 | 1.20 | 24 | ||
| Sterea Hellas | 119 | Evia | 110 | 69 | 41 | 1.68 | 48 |
| Fokida | 1 | 0 | 1 | - | 30 | ||
| Fthiotida | 5 | 2 | 3 | 0.67 | 30 | ||
| Viotia | 3 | 2 | 1 | 2.00 | 48 | ||
| Thessaly | 1 | Trikala | 1 | 0 | 1 | - | 48 |
| West Greece | 14 | Aitoloakarnania | 1 | 5 | 8 | 0.63 | 48 |
| Achaia | 13 | 1 | 0 | - | 60 | ||
| Ammochostos | 67 | 36 | 31 | 1.16 | 24 | ||
| Larnaca | 27 | 12 | 15 | 0.80 | 36 | ||
| Limassol | 97 | 47 | 50 | 0.94 | 36 | ||
| Nicosia | 74 | 31 | 43 | 0.72 | 33 | ||
| Paphos | 177 | 76 | 101 | 0.75 | 24 | ||
Seroprevalence of 1,250 dog sera from Greece.
| Greece | N° of tested sera | N° of interpretable sera | TOSV | SFSV | ARBV | |||
|---|---|---|---|---|---|---|---|---|
| Attica | 410 | 404 | 20 (5) | 343 (84.9) | 2 (0.5) | |||
| Central Macedonia | 129 | 123 | 9 (7.3) | 97 (78.9) | 8 (6.5) | |||
| Crete | 199 | 183 | 2 (1.1) | 100 (54.6) | 5 (2.73) | |||
| East Macedonia and Thrace | 91 | 81 | 2 (2.5) | 56 (69.1) | 4 (5) | |||
| Epirus | 37 | 37 | 2 (5.4) | 27 (73) | 1 (2.7) | |||
| Ionian islands | 79 | 77 | 3 (3.9) | 47 (61) | 0 (0) | |||
| North Aegean | 81 | 75 | 4 (5.3) | 38 (50.7) | 5 (6.7) | |||
| Peloponnese | 60 | 52 | 3 (5.6) | 40 (76.9) | 2 (3.9) | |||
| South Aegean | 30 | 25 | 0 (0) | 16 (64) | 1 (4) | |||
| Sterea Hellas | 119 | 114 | 5 (4.4) | 77 (67.5) | 3 (2.6) | |||
| Thessaly | 1 | 1 | 0 (0) | 1 (100) | 0 (0) | |||
| West Greece | 14 | 13 | 2 (15.4) | 10 (76.9) | 0 (0) | |||
| Female | 710 | 676 | 29 (4.3) | 509 (75.3) | 12 (1.8) | |||
| Male | 540 | 509 | 23 (4.5) | 343 (67.4) | 19 (3.7) | |||
| [6–11] | 36 | 33 | 1 (3) | 21 (63.6) | 0 (0) | |||
| [12–83] | 1,010 | 960 | 39 (4.1) | 700 (72.9) | 26 (2.7) | |||
| [≥ 84] | 204 | 192 | 12 (6.3) | 131 (68.2) | 5 (2.6) | |||
Seroprevalence of 442 dog sera from Cyprus.
| Cyprus | N° of tested sera | N° of interpretable sera | TOSV | SFSV | ARBV | ADAV | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0.094 | 0.280 | |||||||||
| Ammochostos | 67 | 57 | 0 (0) | 15 (26.3) | 1 (1.8) | 2 (3.5) | ||||
| Larnaca | 27 | 20 | 1 (5) | 8 (40) | 1 (5) | 4 (20) | ||||
| Limassol | 97 | 70 | 8 (11.4) | 43 (61.4) | 4 (5.7) | 8 (11.4) | ||||
| Nicosia | 74 | 58 | 4 (6.9) | 37 (63.8) | 1 (1.7) | 9 (15.5) | ||||
| Paphos | 177 | 164 | 18 (11) | 119 (72.6) | 13 (7.9) | 37 (22.6) | ||||
| 0.259 | 0.241 | 0.648 | 0.323 | |||||||
| Female | 240 | 198 | 20 (10.1) | 125 (63.1) | 12 (6.1) | 36 (18.2) | ||||
| Male | 202 | 171 | 11 (6.4) | 97 (56.7) | 8 (4.7) | 24 (14) | ||||
| 0.499 | 0.912 | |||||||||
| [6–11] | 25 | 22 | 1 (4.6) | 13 (59.1) | 1 (4.6) | 2 (9.1) | ||||
| [12–83] | 382 | 317 | 26 (8.2) | 192 (60.6) | 14 (4.4) | 48 (15.1) | ||||
| [≥ 84] | 35 | 30 | 4 (13.3) | 17 (56.7) | 5 (16.7) | 10 (33.3) | ||||
Fig 1Geographic distribution of neutralising antibodies against Toscana virus (panel A), Sandfly fever Sicilian virus (panel B), Arbia virus (panel C) in Greece, using ArcGIS 10). Panel D represent the localisation of regions listed in Table 2.
Fig 2Geographic distribution of neutralising antibodies against Toscana virus (panel A), Sandfly fever Sicilian virus (panel B), Arbia virus (panel C), and Adana virus (panel D) in Cyprus, using ArcGIS 10.